Grant Private Wealth Management Inc Invests $209,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Grant Private Wealth Management Inc acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,518 shares of the company’s stock, valued at approximately $209,000.

Several other large investors have also bought and sold shares of the company. Assenagon Asset Management S.A. bought a new stake in 10x Genomics in the fourth quarter worth about $26,308,000. Point72 Asset Management L.P. acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $27,778,000. ARK Investment Management LLC raised its holdings in shares of 10x Genomics by 11.1% in the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after purchasing an additional 1,193,712 shares in the last quarter. SVB Wealth LLC acquired a new stake in 10x Genomics during the fourth quarter valued at approximately $7,505,000. Finally, Trexquant Investment LP boosted its holdings in 10x Genomics by 196.2% during the fourth quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock worth $8,539,000 after buying an additional 393,854 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

TXG has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Leerink Partnrs cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Canaccord Genuity Group reduced their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Barclays dropped their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.21.

10x Genomics Trading Up 2.1 %

TXG opened at $8.85 on Thursday. 10x Genomics, Inc. has a 1 year low of $8.42 and a 1 year high of $37.74. The stock has a fifty day moving average price of $11.70 and a 200 day moving average price of $14.80. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -5.82 and a beta of 1.93.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, sell-side analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at 10x Genomics

In other 10x Genomics news, Director Alan Mateo acquired 40,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.